# Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma

> **NCT07144384** · EARLY_PHASE1 · RECRUITING · sponsor: **Kirsten Johnson** · enrollment: 40 (estimated)

## Conditions studied

- Skin Basal Cell Carcinoma
- Skin Nodular Basal Cell Carcinoma
- Skin Squamous Cell Carcinoma

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **BIOLOGICAL:** Natural Killer Cell Therapy
- **PROCEDURE:** Surgical Procedure
- **BIOLOGICAL:** Universal Donor Expanded TGF-beta-imprinted NK Cells

## Key facts

- **NCT ID:** NCT07144384
- **Lead sponsor:** Kirsten Johnson
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-16
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07144384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07144384, "Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07144384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*